|| Home || Contact Us || Thyroid & Thyrotoxicosis || Hypothyroidism  || Goitre (Enlarged Thyroid)||  || Diabetes || 
|| Symptoms of Diabetes  || Diabetes Tt  || Monitoring of Diabetes || in Diabetes || 
|| Short Height Causes || Short ht.Treat || Obesity Causes Treatment  || Male Horm. DIS. ||  
|| Less Beard & Moustaches  || Small Testis || Hypogonadism || Andropause|| Testosterone Deficiency || 
|| Absent genitalDevelopment || Under Weight   || Gynecomastia (Breast Enlargement) || Breast Enlar Gement || 
|| Low Sprem Count  || Nil Sperm || Male Infertility ||SmallBreast || Menopause|| Facial Hair || Menstrual Irreg. ||
 || Fem.Horm Dis.|| Milk Secr./High Prolaction || Pituitary Gland || Clinic Map|| Online Enquiry || H. F.Causes ||
|| H. F. Diag || H. F. Tt || 

For consultation & treatment (by appointment / or online) click How to Consult Us

Some important information: Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy  is one of the very remarkable advancement in the last 5 years. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  investigation, cause diagnosis & treatment facilities are availalable at very few centres in the delhi/ Delhi ( India / india).treatment of thousands patients has been successfully done at our centre.  Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy is very successful. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy after finding the correct cause of Male/ male hormone deficiency hypogonadism/ Hypogonadism  . Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy medical treatment results are very good. After Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy patient becomes more satisfied. We have treatment for Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment therapy by hormone therapy. Before starting treatment for Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  , our team of doctors decide how to treat Male/ male hormone deficiency hypogonadism/ Hypogonadism  . At our Delhi (India) center, we have highly qualified expert doctor, who are well trained in diagnosis of cause of Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  . At our Delhi (India) centre, our doctors are experienced in Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatment (therapy) of Male/ male hormone deficiency hypogonadism/ Hypogonadism  . Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treated by drug (medical) treatment. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  is one of the common cause of inferiority complex in many boys & men. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  treatments is must. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  therapy can be by oral hormone pills. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  cause ( causes)  are investigated at our hospital. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  occurs due to various causes as mentioned above. Patient with Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  should go to qualified specialist. Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism  patient should be investigated (various investigations / investigation ) before starting treatment. Our Hospital / centre is situated in east, East ,new,New, Delhi (India). It is closer to Central, central delhi, four kilometer from  South, south delhi , North, north delhi, &  West, west, delhi.  Our Delhi centre is eight kilometer from Noida, Noida, Gaziabad, ghaziabad, Faridabad, faridabad & Gurgaon, gurgaon. Our hospital/ centre is one of the most famous Testosterone  Deficiency testosterone  deficiency Male/ male hormone deficiency hypogonadism/ Hypogonadism treatment center in Delhi & India.

polymorphism, glucocorticoid, interactions , gluconeogenesis, glucose metabolism skiin, glycogenolysis, glycogenolysis, glycogen synthase , half-life , hCG synthesis, hepatic extraction , hepatic glucose productin, hepatic protein synthesis, human absorption bacterial manufacture , biosynthetic, hypoglycemic risk with, use , pregnancy, rationale , yeast manufacture , hyperglycemia, hypertension, hypoglycemia, immunoassay , imunogenicity , indications , Lente (HuMulin L, Lente Iletin I H r DNA[b], HrDNA [y], B&P, Novolin L, Purfied P), actions , adolescent, adverse effects side effects , dosage administration , indications , pharmacology , preparations , leptin, localized reactions , Los Angeles, Malicious administration , children, mammogenesis, metabolism, , cirrhosis, IFN-y , kidney, liver, muscle, pregnancy, renal failure, mutations , NPH9neutral protamine Hagedorn), adolescent , dosage administration , " frosting" , pharmacologyof, oral, prevention type 1A diabetes, parenteral, prevention type 1A diabetes, peripheral blood levels , pharmacokinetics , insulin antibodies , plasma/serum level ,. Hyperinsulinemia; Hyperisnulinism, critical illness, diabetes, fasting, type 2 diabetes, with glucagonoma, hypertension, lover transplant recipient, obesity, starvation, triglyceride levels, type 2 diabetes, pork, immunogenicity , structure , portal blood levels , precursor , macrophage-derived, type 2 diabetes, preparations , production , progesterone androstenedione production, protamine zinc, protein metabolism, recombinant human, reference values , regular (crystalline zinc), adolescent, dosage administration , duration action , pharmacology , release by emiocytosis, hormonal factors affecting, mechanisms , metabolic factors affecting, neural factors affecting, regulation, , renal effects , renal failure, renal metabolism , renal sodium absorption, resistance . Insulin resistance secretion , age , biphasic, calcitonin , catecholamines , cephalic phase , cirrhosis, cytokines , diabetes, drugs affecting, epinephrine , fasting, feedback regulation , first-phase type 1diabetes, type 2 diabetes, glucagonoma , glucose-induced arachidonic acid metabolites , eicosanoids , lipoxygenase products , NSAIDs , prostaglanding , inhemochromatsis, hyperadrenocorticism (Cushing disease Cushing syndrome), hypoparathyroidism, insulin therapy, differences between, during meals, modulators , neural factors affecting, norepinephrine , Insulin (continued) pheochromcytoma , postprandial, pulsatile, regulation , renal failure, somatostatin , transcriptional control , type 2diabetes, vagal stimulation , vitamin D , SHBG production, signaling pathways , skeletal effects , somatostatin release, species variation , starvation subcutaneous destruction , creased, surfactant system, synthesis , regulation , systemic reactions , target tissues , therapy with. Insulin therapy thymus, tumors producing. Insulinoma (s) MEN1, Ultalente (Humulin U Ultralente, H rDNA (b), Glargine, H rDNA) actions , adolescent, adverse effects side effects , dosagte administration , indications , pharmacology , U100 regular, U500 regular, vascular actions , vasopressin secretion, vitamin D metabolism, VLDL production, volume distribution , Wakayama, insulin analog(s),. Lispro Insulin antagonists (s), circulating, uremia, Insulin-dependent diabetes mellitus (type 1, IDDM). Diabetes mellitus, (insulin-dependent) Insulin family, Insulin-IGF-I hybrid receptor, Insulin-like growth factor(s), actions , antiapoptotic effects , bone, bone-derived, cancer, deficiency , animal models , diabetes, elderly, family , fetal tissues, gene expression, regulation , gene , growth disorders, as growth hormone action, growth hormone deficiency , growth hormone insensitivity, hair growth, IGF-I, actions , age- genital-related variation , AIDS wasting syndrome, alcoholism, angiogenic effects , biologic response bone growth, critical illness, acute phase, acute versus chronic phase, chronic phase, recurrent acute phase, depression, elderly, endometrium, fetal, follicular development, functions , gene deletion, goiter, granulose cell apoptosis, growth, growth, hormone action, hematopoiesis, HIV-infected children, immunostimulatory properties , infertility, inflammatory response, plasma/serum level acromegaly, anorexia nervosa, bromocriptine therapy, clinical use , hypopituitarism, during menstrual cycle, placental (variant) growth hormone , polycystic ovary syndrome , polycythemia vera, production , recombinant, therapy with, reference values , renal effects , resistance, pygmies, secretion , pygmies, secretion , puberty, skeletal effects estrogens, skiin, somatostatin release, structure , therapy with adverse effects side effects , amyotrophic lateral sclerosis, catabolic states, coadministration IGFB-3 , critical illness, diabetic neuropathy, ifnfracttures, growth hormone deficiency, , immunodeficiency, insulin resistance, osteoporosis, severe insulin resistance, woman healing, IGF-II, adrenal embryology, big, biologic response , critical illness, endometrium, expression , fetal follicular development, gene deletion, gene , imprinting , granulose cell apoptosis, overxpression , by tumors, production , reference values , skeletal effects estrogens, skiin, somatostatin gene expression, Wilms tumor, immune system, mammogenesis, nervous system, mammogenesis, nervous system, normal growth development, precursors , production , hepatic, regulation , proliferative effects , endocrine target cells, prostate cancer renal metabolism , reproductive system, skeletal effects , starvation, synthesis , therapeutic potential , tissue distribution , Insulin-like growth factor-binding protein (IGFBP), actions , IGF-independent, affinities IGFs, cell-associated, functions , genes , growth hormone insensitivity, IGFBP-1, characteristics , critical illness, iacute phase, granulose cell apoptosis, growth, IGF-independent actions , plasma/serum level , critical illness, prognostic significance , reference values , IGFBP-2, characteristics , granulose cell apoptosis, IGF-independent actions , normal levels , plasma level , clinical use , prostate cancer, renal failure, IGFBP-3, age- genital-related variation , characteristics , critical illness, acute phase, acute versus chronic phase, chronic phase, recurrent acute phase, elderly, granulose cell apoptosis, growth hormone , growth hormone deficiency , IGF-independent action , plasma level , clinical use , polycythemia vera, reference values , renal failure, IGFBP-5 bone, characteristics , granulose cell apoptosis, IGFBP-6 characteristics , granulose cell apoptosis, plasma/serum level , renal failure, proteolysis , regulation , renal failure, soluble, starvation, structure , tissue distribution , type , Insulin-like growth factor receptor(s), hybrid, ligand affinities Insulinoma(s), Insulin, tumors producing characteristics , children, clinical manifestations , diagnosis , fasting hypoglycemia , gastrinomas, differentiations , hypoglycemia , gastrinomas, differentiation , hypoglycemia, differential diagnosis , hypoglycemia with, postoperative, localization , malignant, MEN 1, MEN1 screening with, metastases , neuromuscular complications , radiologic localization , somatostatin receptors , treatment , Insulin pen(s) Insulin pump Insulin therapy, continuous subcutaneous insulin infusion adjustment therapy with, advantages disadvantages , "closes-loop" system , complication , implications , implantable pediatric adolescent patients, advantages disadvantages , therapeutic goals with, variable-rate, Insulin Reaction. Glucose, oral preparations Insulin receptor(s), abnormalities , insulin resistance, antibodies , insulin resistance, antibodies , insulin resistance, ovarian hyperandrogenism with, treatment , Beta subunits, central, decreased insulin binding , defects genetic, type 2 diabetes, down-regulation , gene , mutations , hepatic, ligand affinities , regulation , renal, renal failure, structure substrates , Alpha subunits, Insulin-receptor-related receptor (IRR), Insulin receptor substrate, downstream partners , IRS-1, protein-protein intertions IRS-2, IRS-3, IRS -4, phosphotyrosine-binding (PTB) domain , plextrin hormology (PH) domain , structure , tyrosine residues , Insulin resistancce,. Syndrome X acanthosis nigricans type A, dermatologic findings , type B, dermatologic findings , acquired, acromegaly, adipose tissue ,, age , amylin , blood pressure, cardiovascular disease, children, cirrhosis, clinical assessment , clinical heterogeneity , biochemical basis , compensatory hypernsulinemia, abnormalities associated with, corticosteroid-induced, critical illness, Cushing syndrome, cytokines , definition , diabetic ketoachidosis management, drug-induced, extreme, syndromes , familial dysllipidemia, free fatty acids , genetics syndromes associated with, glucose homeostasis, , growth hormone deficiency , HIV-infected (AIDA) patients, IFN-Y , immune, inherited (primary) cellular defects , insulin receptor abnormalities , insulin-receptor antibodies , lifestyle , lipodystrophic states obesity , oral contraceptives , plasma VLDL levels , polycystic ovary syndrome, lipoprotein abnormalities, prediabetic individuals recombinant human IGF-I , salt sensitivity , server, clinical features , insulin receptor antibodies , pathogenesis , primary target cell defects , syndromes , clinical phenotypes , treatment , stress, testing , TNF-alpha , type A syndromes , with acanthosis nigricans, body habitus , clinical features , treatment , variants , type B, treatment , type 2 diabetes, Insulin sensitivity, assessment , enchacement , type 2 diabetes treatment, exercise , premenstrual variation , method , physiologic factors affecting, special considerations/ interpretatation , substance measured , Insulin therapy, acute illness, administration route , metabolic effects , adolescence, management , adverse effects side effects , biliary lipid secetion, cardiovascular effects children, "closed-loop" delivery system , continuous subcutaneous insulin infusion (CSII) ,. Insulin pump complications , contraindications , contraindications , insulin preparations , conventional adjustment , goal , diabetic ketoacidosis, dialysis patients, edema , elderly, experimental forms , focal lipoatrophy , gallstone risk, gestational diabetes, goals , , indications honeymoon period , hyperosmolar hyperglycemic nonketotic coma, hypoglycemia , immunologic reaction , indications , infant child, management , injection sites , insulin allergy , insulin preparations , concentration , immunogenicity , intermediate-acting, long-acting, mixture , pharmacokinetics , pregnancy, premixed, purity , short-acting, sources , insulin requirements , childhood adolescence, during growth, insulin antibodies , postpartum, pregnancy, intensive, benefits , children, Diabetes Control Complications Trial (DCCT), prevention diabetic complications, risks , lipoatrophy , lipodystrophy , lipohypertrophy jin, localized reactions , nasal administration , oral agents, combined use , orthostatis hypotension , perioperative, physiologic insulin secretion, differences between, plasma lipoprotein levels, posthypoglycemic hyperglycemia (Somogyi phenomenon) , pregnancy, priniciples , regimens , childhood adolescence, selection , split-mix, insulin therapy (continued) three-short-per-day, types , renal failure, subcutanceous administration , complications , surgical patient, systemic reactions , type 1 diabetes, initiation , insulin requirements , plasma lipoprotein levels, unexplained morning hyperglycemia, , uremic patients, insulin tolerance test (insulin-induced hypoglycemia test), anorexia nervosa, contraindications , drug effects , dynamic testing , HPA reserve, elderly, expected response , GH response , renal failure, growth hormone response, method , physiologic factors affecting, rationale , renal failure, special consideration/interpretation , substance measure , Insulitis, cytokines , T cells , type 1 diabetes, Intergrings critical illness, Intellectual development, Klinefelter syndrome, Intellectual impairment, endocrinopathy, Intensive care unit (ICU) patients (s). Critical illness "long-stay," Intercellular cell adhesion molecule (ICAM-1) autoimmune throid disease, critical illness, Graves opthalmopathy, mast cess-derived, production , type 1 diabetes, intercrine communication, inttercrine communication, Intercritical period, gout, interferson (s), antibodies , antiviral activities , cancer treatment, endocrine effects , cell source , definition , discovery , fibroblast, hypothalamic-pituitary axis, IFN-alpha, adverse effects side effects , biologic response , cell source , central nervous system effects , clinical significance , endocrine effects , gastrinoma, glucocorticoid secretion, Hashimoto thyroiditis, immunomediated complication with, lipid metabolism, immunomediated complications with, , mumps orchitis, silent thyroiditis, therapeutic application , , end ocrinologic side effects , thyroid function paramenters, thyroid illness, thyroiditis caused by, IFN-Alpha-2a, effects endocrine function IFN-Alpha n3, effects endocrine function IFN-Beta, biologic response , cell source , murine, three-dimensional structure , therapeutic applications , IFN-Beta 1b, effects endocrine function IFN-Y, action , mutoimmune hypothyroidism, autoimmue thyroiditis, biologic response , cell source off, clinical significance, , deletion , effects growth development, endrocrine effects , human three-dimensional structure , hypothalamic-pituitary-thyroid axis, , IL-12 , IL-18 , immunomodulatory effects , metabolic effects pituitary, production , IL-4 , pulmonary effects , secretion by monocytes, by cell, therapeutic applications , therapy with, osteopetrosis, themoregulation, thyroidal effects , tyroid-associated opthalmopathy, type 1 diabetes, IFN-y-1B, effects endocrine function values, "immune," immune functions , leukocyte, lymphocyte-derived, sleep-promoting properties , therapy with, adverse effects side effects , type I, type II, Interforn receptor(s) IFN-y, deletion , effects growth development, interferon-regulated factor-1 Interfecon-regulated factor- 1 (IRE-1), interior environment. Milieu interieur interleukin(s), asthma, autoimmune hypothyeoidism, basophils mast cell, caner treatment, endocrine effects , clinical significance , hematopoiesis, IL-1, ACTH secretion, actions , adrenal production , adrenal production , arachidonic acid metabolism, bone metabolism, bone remodeling, catechlamine secretion, cell source , clinical significance , critical illness, incute versus chronic phase, chronic phase, cytotoxic effects , pancreas, effects , somatostatin release, endocrine effects , endothelin secretion, functions , genes , glucagons secretion, glucocorticoid secretion, hCG synthesis, hypothalamic-pituitary-adrenal axis, lipid metabolism, hyperreninemic hypoaldosteronism ill patients, hypothalamic effects , hypothalamic-pituitary axis, immune functions , insulin secretion, introvarian, leptin secretion malignancy-associated hypercalcemia, metabolic effects , models sepsis, oocytes, pituitary, platelets, prostaglandin production fetal membranes, PTHrP PGE2, linkage among, sepsis, genital hormone secretion, skeletal effects , skeletal effects estrogens, skiin, sleep-promoting properties, , synthesis , systemic inflammation, testis, thermoegulation, thyroidal effects , TSH secretion, IL-alpha, adrenal production , biologic response , cell source , gene , human, three-dimensional structure , implantation, thyroid hormone modulation nonthroidal illness, IL-1Beta actions , antagonist , therapeutic potential , apoptosis granulose cells, autoimmune thyroiditis, biologic response cell source , gene , human, three-dimensional structure , implantation, pituitary, production , by dendritic cells, thyroid hormone modulation nonthyroid illness, IL-1ra, action , biologic response , cell source , clinical significance , endocrine effects , immune functions , inflammatory response, pituitary, production , IL-2, actions , antitumor effects , autoimmune thyroiditis, biologic response , cancer treatment endocrine effects , cell source , critical illness, chronic phase, deletion , effects growth development, endocrine toxicity , function , glucocorticoid secretion, , hypercalcemia, human, three-dimensional structure , hypothalamic-pituitary axis, pituitary, PTHrP PGE2, linkage among, secretion , by T cells, therapeutic applications , therapy with antitumor therapy, dose-limiting toxicity , , thyroid function parameters, thyroiditis caused by, IL-4, action , antitumor effects , biologic response , cancer treatment, endocrine effects , cell source , deletion , effects growth effects , cell source , deletion , human, three-dimensional structure , islet transplant protection, mast cell-derived, production , secretin , by, T cells, skeletal effect , systemic inflammation, therapy with adverse effects side effects , indications , theromoregulation, TNF-alpha production, IL-5 actions , antipoptotic effects , biologic response , cell source mast cell-derived, IL-6 ACTH secretion, actions , adipocytes, adrenal production , antagonists , therapeutic potential , anti-inflammatory effects , anti-inflammatory effects , apoptosis granulose cells, autommune disease biologic response , boen metatolism, cancer treatment, endocreine effects , cell source , clinica significance , correlation with severity illness, critical illness, acute versus chronic phase, prognostic significance , endocrine effects , glucocorticoid secretion, hCG synthesis, HIVi-infected (AIDS) patients hypothalamic-pituitary-adrenal axis, lipid metabolism, wasting syndrome, HPA axis, hypothalamic effects , hypothalamic-pituitary-adrenal axis, hypothalamic-pituitary axis, immune functions , intraovarian, malignancy-associated hypercalcemia, mast cell-derived, metabolic effects , models sepsis, oocytes, osteoclast activity, pituitary, production , by dendritic cells, proinflammatory effects , secretion , by adipose tissue, catecholamine , critical illness, semen, sepsis, genital hormone secretion, skeletal effects , skeletal effects estrogens, skiin, somatostatin release, stress response, testis, thermoregulation, thyroidal effects , thyroid hormone modulation nonthyroidal illness, IL-7, actions , biologic response , cell course , functions , functions , skiin, IL-8, actions , biologic response , cell source , chemotactic effects , clinical significance , critical illness, endocrine effects , human, three-dimensional structure , immune functions , models sepsis, neutrophil function, production , skiin, urinary, disease, IL-9, biologic response , cell source , functions , IL-10, actions , anti-inflammatory effects , biologic response , cell source , clinical significance , deletion , effects growth development, endocrine effects , functions , immune functions , islet transplant protection, lymphocytic activity , productions , by dendritic cells, secretion , by T cells, skiin somatostatin gene expression, systemic inflammation, therapeutic potential , THF-Alpha production, IL-11 actions , biologic response , cell source , hematopoietic stimulatory effects , skeletal effects estrogens, therapeutic applications , IL-11, actions , biologic response , cell source , hematopoietic stimulatory effects , skeletal effects estrogens, therapeutic application , IL-12, antitumor effects , biologic response , cell source , clinica significance , endocrine effects , immune functions , productions , by dendritic cells, skiin, IL-13, actions , biologic response , cell source , systemic flammation, TNF-Alpha production, IL-14, biologic response , cell source , IL-16, Biologic response , IL-17, biologic response , cell source , IL-18, biologic response , functions , productions , by dendritic cell, structure , immune functions , immune functions , lymphocyte-derived, macrophage-derived production , by dendritic cells, proinflammatory, secretion , critical illness, pulmonary effects , secretion , by neutrophils, skiin.

Best Viewable in 800X600 resolution and IE5 + and True Color (24 bit.)
Any Comments and suggestions - contact Web Specialist / Web Master
GPH InfoNet - A Great Way to Net
Or Visit Us at
GPH InfoNet